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httpcense.Abstract Background: Diabetes mellitus (DM) is a leading public health problem with increasing
incidence and long term complications. These complications are mainly a consequence of macrovas-
cular and microvascular damages of the target organs. The presence of an extensive microvascular
circulation and abundant connective tissue in the lungs, raises the possibility that lung tissue may be
a target organ in diabetic patients.
Objectives: To study the impact of DM and its control on pulmonary function and cardiopulmo-
nary exercise tests.
Methodology: This is a cross-sectional study carried out on diabetic mellitus patients (type I or
type II n= 30) group II divided into two subgroups (group IIA) controlled diabetes (HbA1c < 7%)
(n= 15) and uncontrolled diabetes (group IIB) (HbA1cP 7% (n= 15). The control group (group I)
was non diabetic healthy (n= 15). The following pulmonary function parameters were recorded:
Forced Expiratory Volume in the ﬁrst second (FEV1), Forced Expiratory Volume percent (FEV1/
FVC %), Forced Expiratory Flow 25–75% (FEF 25–75%), peak expiratory ﬂow (PEF) and
MVV. Also maximum aerobic power (VO2 max) using cardiopulmonary exercise test was measured.
Results: Themean FEV1, FEV1/FVC%, PEF, FEF 25–75%,MVV andVO2max values were low
in diabetics (p value <0.05) compared to non-diabetics. Also, uncontrolled diabetics show a greater
decrease in these values than controlled diabetics.
Conclusion: The ﬁndings of the present study suggest that, the lung is a target organ for damage in
DM and diabetics show a decrease in PFTs and VO2 max compared to non-diabetics. And this dete-
rioration is exaggerated in uncontrolled diabetics.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.1112143143.
(M.M. El-Habashy).
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Diabetes mellitus describes a metabolic disorder of multiple
etiology, characterized by chronic hyperglycemia with distur-
bances of carbohydrate, protein and fat metabolism, resulting
from defects in insulin secretion or insulin action or both [1].is. Production and hosting by Elsevier B.V.
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472 M.M. El-Habashy et al.Diabetes mellitus is a leading public health problem with
increasing incidence and long term complications such as dia-
betic nephropathy, diabetic neuropathy, diabetic retinopathy
etc. These complications are mainly a consequence of macro-
vascular and microvascular damages of the target organs [2].
Deterioration of pulmonary functions in DM is going to be
eighty percent of all diabetics from the entire world population
[1]. In 2000 the number of people with diabetes was 31.7 mil-
lion and it is expected that by 2030 this will increase to
79.4 millions [3]. Several factors contributing to this include
greater longevity, obesity, unsatisfactory diet, sedentary life-
style and increasing urbanization. The cause of clinical diabe-
tes is absolute or relative deﬁciency of insulin. The presence of
an extensive microvascular circulation and abundant connec-
tive tissue in the lungs raises the possibility that lung tissue
may be affected by microangiopathy process and non-enzy-
matic glycosylation of tissue proteins, induced by chronic
hyperglycemia, thereby rendering the lung a ‘‘target organ’’
in diabetic patients. Since normal lung mechanics and gas ex-
change are inﬂuenced by the integrity of pulmonary connective
tissue and microvasculature, abnormalities in either of these
two structural components of the lung may lead to the devel-
opment of measurable abnormalities of pulmonary function
[4]. In 2004, Wendy et al. observed that a 10% decrease in
FEV1 was associated with 12% increase in all-cause mortality
[5]. As measures of airﬂow limitation predict all-cause mortal-
ity in diabetes, intensive glycemic management may reduce the
risk of death through improved ventilatory function indepen-
dent of other beneﬁcial effects. So, the assessment of pulmon-
ary function is an important investigation because early
detection of functional impairment and its appropriate treat-
ment will help to reduce morbidity and mortality [5].
Cardiopulmonary exercise testing (CPET) is being utilized
to investigate cardiac and respiratory function. It can be used
to identify an abnormality in patients with exercise intolerance
or exercise related symptoms. It is also useful to evaluate pa-
tients with cardiovascular disease including cardiac failure
and before heart and lung transplantation [6].
The VO2max (ameasure included in CPET) is the maximum
amount of oxygen that the body can use in oneminute. VO2max
(also maximal oxygen consumption, maximal oxygen uptake,
peak oxygen uptake or maximal aerobic capacity) is the maxi-
mum capacity of an individual’s body to transport and use oxy-
gen during incremental exercise, which reﬂects the physical
ﬁtness of the individual. The name is derived from V – volume,
O2 – oxygen,max –maximum.VO2max is expressed either as an
absolute rate in liters of oxygen per minute (L/min) or as a rela-
tive rate in milliliters of oxygen per kilogram of bodyweight per
minute (i.e., mL/(kg min)). The latter expression is often used to
compare the performance of endurance of sports athletes [7].
Accurately measuring VO2 max involves a physical effort
sufﬁcient in duration and intensity to fully tax the aerobic en-
ergy system. In general clinical and athletic testing, this usually
involves a graded exercise test (either on a treadmill or on a cy-
cle ergometer) in which exercise intensity is progressively in-
creased while measuring ventilation and oxygen and carbon
dioxide concentration of the inhaled and exhaled air. VO2
max is reached when oxygen consumption remains at a steady
state despite an increase in workload [7].
There are several factors that affect VO2 max, including
muscle mass, blood oxygen levels, lung capacity and general
ﬁtness level. The maximum VO2 is the ﬁrst measurement tobe examined because it establishes whether the patient’s phys-
iologic responses allow normal maximal aerobic function or
not. Other measurements are then used to differentiate the
cause of any exercise limitation whether or not the subject
reaches his/her predicted maximum VO2. Tests measuring
VO2 max can be dangerous in individuals who are not consid-
ered normal healthy subjects, as any problems with the respi-
ratory and cardiovascular systems will be greatly exacerbated
in clinically ill patients. Thus, many protocols for estimating
VO2 max have been developed for those for whom a tradi-
tional VO2 max test would be too risky. These generally are
similar to a VO2 max test, but do not reach the maximum of
the respiratory and cardiovascular systems and are called
sub-maximal tests [8].
Another estimate of VO2 max, based on maximum and
resting heart rates, was created by a group of researchers from
Denmark [9]. It is given by:
VO2max ¼ 15HRmax
HRrest
This equation uses maximum heart rate (HRmax) and rest-
ing heart rate (HRrest) to estimate VO2 max in mL/(kgÆmin).
‘‘Maximal oxygen uptake (VO2 max) is widely accepted as
the single best measure of cardiovascular ﬁtness and maximal
aerobic power. Absolute values of VO2 max are typically 40–
60% higher in men than in women [10].’’
Aim
The aim of the present study was to assess the pulmonary func-
tion test in patients with DM either controlled or not and also
to study the changes that may occur in their VO2 max.Materials and methods
The present study (a cross-sectional study) included 30 patients
group II; 15 patients with controlled DM (group IIA) and 15
patients with uncontrolled DM (group IIB) admitted to chest
and internal medicine departments, Menouﬁya University hos-
pitals in the period from February 2013 to August 2013. We
also included 15 healthy non diabetic subjects who volunteered
as a control group.
Inclusion criteria: patients with DM either type I or II.
Group IIA: included in the study were patients with con-
trolled diabetes which is deﬁned as HbA1c <7% and were
15 patients and the other group; group IIB was patients with
uncontrolled diabetes which is deﬁned as HbA1cP 7% and
were 15 patients. The subjects of both genders in the age group
between 25 and 60 years are included. 15 healthy non diabetic
subjects were studied as a control group; group I.
Exclusion criteria: subjects with a past history of smoking,
hypertension (HTN), respiratory diseases (Acute or chronic),
chest wall injuries, congestive cardiac failure (CHF), and chest
wall deformities were excluded from the study.
The subjects were properly explained about the objectives,
methodology, expected outcome and implications of the study
and written informed consents were obtained from them.
(1) Full history taking and complete clinical examination.
(2) Routine laboratory investigations including complete
liver and kidney functions, complete blood count
Impact of diabetes mellitus and its control 473(CBC), erythrocytic sedimentation rate (ESR), and lipid
proﬁle.
(3) Fasting and post-prandial blood glucose levels.
(4) Urine glucose and acetone.
(5) Electrocardiogram (ECG) and echocardiography, if
needed.
(6) Chest X-ray (postero-anterior and lateral views if
needed).
(7) Pulmonary function tests: Pulmonary function tests were
done for all studied patients. The following parameters
in PFTs were measured [11]:
(a) Forced Expiratory Volume in the ﬁrst second (FEV1).
(b) FEV1/FVC ratio.
(c) Peak expiratory ﬂow (PEF).
(d) Forced mid-expiratory ﬂow (FEF 25–75%).
(e) Maximal voluntary ventilation (MVV).
(8) Cardiopulmonary exercise test was used to measure VO2
max:
Cardiopulmonary exercise protocol [12]
The goal of CPET protocols is to stress the organ systems in-
volved in the exercise response in a controlled manner. In our
research (using Treadmill exercise testing), incremental exer-
cise testing protocol was used as a modiﬁcation of Balk’s pro-
tocol [13]. The test duration is 12 min divided into: 3 min
warming up, 3 min rest, and 6 min exercise. The speed starts
by 3 Km/h during warming up stage, then the speed decreases
gradually until it stops in resting stage, then the speed increases
gradually to reach 3 Km/h during exercise and the subject in-
creases the speed manually until he can tolerate.
Statistical methodology
The data collected were tabulated & analyzed by SPSS (statis-
tical package for the social science software) statistical package
version 11 on IBM compatible computer. Quantitative data
were expressed as mean & standard deviation (X ± SD) and
analyzed by applying Student’s t-test for comparison of two
groups of normally distributed variables. Qualitative data were
expressed as number and percentage (No & %) and analyzed
by applying chi-square test (v2). Whenever the expected values
in one or more of the cells in 2 · 2 tables were less than 5, ﬁsh-
er’s exact test was used instead.
Results
Data are mean ± SD age and anthropometric values are not
statistically signiﬁcant (p> 0.05) (Fig. 1).
In Table 1 group I was compared with group II, there was a
signiﬁcant decrease in FEV1, FEV1/FVC% and FEF 25–75%
between both groups. While there was a non-signiﬁcant differ-
ence regarding MVV.
Table 2 shows that there was a statistically signiﬁcant
difference between groups I and IIA regarding FEV1,
FEV1/FVC, FEF 25–75% and PEF but there was no signiﬁ-
cant difference between them regarding FEF25–75 and MVV.
Table 3 shows that there was a statistically signiﬁcant
difference between groups I and IIB regarding
FEV1, FEV1/FVC, PEF, FEF25–75 and MVV.Table 4 shows that there was a statistically signiﬁcant
difference between groups IIA and IIB regarding
FEV1, FEV1/FVC, FEF25–75 and MVV.
Table 5 and Fig. 2 show that there was a statistically
signiﬁcant difference between groups I, IIA and IIB regarding
VO2 max/kg (ml/min/kg) and also all parameters in pulmon-
ary function.Discussion
Our study showed all the pulmonary parameters, that is, there
was a signiﬁcant decrease in pulmonary function tests among
diabetic patients (FEV1, FEV1/FVC%, PEF, FEF 25–75%
and MVV) compared with healthy controls. Also in diabetic
subjects (uncontrolled), there was a signiﬁcant reduction in
FEV1, FEV1/FVC%, PEF, FEF 25–75% and MVV) as com-
pared with the controlled diabetic patients. This is in accor-
dance with previous studies [14–16]. Meta-analysis by van
den Borst et al. showed that DM is associated with statistically
signiﬁcant, impaired pulmonary function in a restrictive pat-
tern. Moreover, these results were irrespective of body mass in-
dex (BMI), smoking, diabetes duration, and HbA1c levels [17].
Uchida, et al. found that there was a decreased pulmonary dif-
fusing capacity in patients with diabetes with perfusion defect
on ventilation perfusion scintigrams [18]. It was not possible
for us to analyze the pulmonary diffusing capacity because
of practical difﬁculties. Davis et al. conducted a study in Wes-
tern Australia in a large number of patients of type 2 DM.
They found that VC, FVC, FEV1, and PEFR decreased at
an average of between 1.1% and 3.1% of predicted values/year
in DM patients [5]. Ehrlich et al. [19] showed that patients with
type DM were at increased risk of several pulmonary condi-
tions like – asthma, Chronic Obstructive Pulmonary Disease
(COPD), ﬁbrosis, and pneumonia. Normal lung mechanics
and gas exchange are inﬂuenced by the integrity of the pul-
monary connective tissue and microvaculature. Acceleration
of aging process in connective tissue cross links and the pres-
ence of nonenzymatic glycosylation and modiﬁcation of alveo-
lar surfactant action cause reduction in PFTs [20]. There have
been reports of histopathological changes in the diabetic pa-
tients. In the study by Weynand et al. [21], it was found that
alveolar epithelium, endothelium capillary, and basal laminaes
were thickened in the lungs on electron microscopy, when
compared with the controls. Diabetic microangiopathy might
be existing in the pulmonary vascular bed. Moreover, reduced
pulmonary capillary blood volume was found, favoring the
evidence of microangiopathy. This could lead to redistribution
of the pulmonary circulation, resulting in well ventilated areas
to become under-perfused [22]. There are certain studies show-
ing no correlationship between HbA1c and PFTs [23,24]. They
argued that HbA1c levels are indicators of glycemic control for
a short period of 1–2 months, it was not adequate to conclude
that the plasma glucose level was not related to decreased
PFTs. The thickening of the alveolar wall due to the increased
amounts of collagen and elastin in basal lamina results in
microangiopathy. There was a signiﬁcant reduction in FEF
25–75% among diabetics compared to controls, shows a lower
airway caliber and higher airway resistance and this ﬁnding
was similar to Ashapherwani et al. and Malcom Sandler
et al. [20]. The role of strict glycemic control on pulmonary










Age (Yrs) Weight (Kg) Height (Cm) BMI (Kg/m2)  DM   I  DM II
Group (I) control
(No. 15)
Group (II A) 
(No. 15)
Group (II B) 
(No. 15)
Figure 1 Domographic parameters among the studied groups.
Table 1 Comparison of groups I and II regarding pulmonary functions.
Group (I) control (No. 15) Mean ± SD Group (II) (No. 30) Mean ± SD t Test p Value
FEV1 89.86 ± 8.36 79.30 ± 9.30 3.71 0.001**
FEV1/FVC 96.56 ± 6.38 84.11 ± 9.57 4.55 0.001**
PEF 90.00 ± 5.95 82.94 ± 7.09 3.3 0.002**
FEF25–75 96.74 ± 1.96 94.59 ± 3.01 2.50 0.02
*
MVV 98.95 ± 1.98 96.65 ± 5.49 1.57 0.12
Table 2 Comparison of groups I and IIA regarding pulmonary functions.
Group (I) control (No. 15) Mean ± SD Group (IIA) (No. 15) Mean ± SD t Test p Value
FEV1 89.86 ± 8.36 82.08 ± 12.40 2.015 0.04*
FEV1/FVC 96.56 ± 6.38 89.24 ± 11.30 2.185 0.03*
PEF 90.00 ± 5.95 84.36 ± 8.56 2.096 0.04*
FEF25–75 96.74 ± 1.96 95.82 ± 2.99 0.995 0.33
MVV 98.95 ± 1.98 98.46 ± 2.44 0.608 0.55
* p Value is signiﬁcant if <0.05. SD, standard deviation.
Table 3 Comparison of groups I and IIB regarding pulmonary functions.
Group (I) control (No. 15) Mean ± SD Group (IIB) (No. 15) Mean ± SD t Test p Value
FEv1 89.86 ± 8.36 76.53 ± 3.01 5.814 0.01*
FEv1.FVC 96.56 ± 6.38 78.97 ± 2.34 10.024 0.01
PEF 90.00 ± 5.95 81.53 ± 5.16 4.166 0.02*
FEF25–75 96.74 ± 1.96 93.37 ± 2.57 4.040 0.04
*
MVV 98.95 ± 1.98 94.84 ± 7.03 2.180 0.038*
* p Value is signiﬁcant if <0.05.
Table 4 Comparison of groups IIA and IIB regarding pulmonary functions.
Group (IIA) (No. 15) Mean ± SD Group (IIB) (No. 15) Mean ± SD t Test p Value
FEv1 82.08 ± 12.40 76.53 ± 3.01 1.7 0.05*
FEv1.FVC 89.24 ± 11.30 78.97 ± 2.34 3.4 0.002**
PEF 84.36 ± 8.56 81.53 ± 5.16 1.1 0.2
FEF25–75 95.82 ± 2.99 93.37 ± 2.57 2.4 0.02
*
MVV 98.46 ± 2.44 94.84 ± 7.03 1.88 0.05*
* p Value is signiﬁcant if <0.05.











Group (II A) 
(No. 15)
Group (II B) 
(No. 15)
Figure 2 Comparison of the three groups regarding VO2/kg (ml/min/kg).
Table 5 Comparison of the three groups regarding pulmonary function and VO2 max/kg (ml/min/kg).
Group (I) control (No. 15)
Mean ± SD
Group (IIA) (No. 15)
Mean ± SD






FEv1 89.86 ± 8.36 82.08 ± 12.40 76.53 ± 3.01 8.7 0.01**
FEv1.FVC 96.56 ± 6.38 89.24 ± 11.30 78.97 ± 2.34 20.2 0.001**
PEF 90.00 ± 5.95 84.36 ± 8.56 81.53 ± 5.16 6.2 0.001**
FEF25–75 96.74 ± 1.96 95.82 ± 2.99 93.37 ± 2.57 7.04 0.01
*
MVV 98.95 ± 1.98 98.46 ± 2.44 94.84 ± 7.03 3.8 0.003**
VO2 max/kg (ml/
min/kg)
94.8 ± 3.4 91.8 ± 4.03 88.88 ± 7.08 5.08 0.001**
** Highly signiﬁcance difference.
Impact of diabetes mellitus and its control 475needs further studies. The impairment in PFTs can lower the
threshold for clinical manifestations of acute or chronic lung
disease. There was a parallel association between poor control
of DM and reduction in pulmonary function tests.
The present study prospectively determined that VO2 max
was greater in healthy subjects versus diabetic patients. Also
VO2 max was greater in diabetes with good versus poor glyce-
mic control. Similar results were published in subjects when
Niranjen et al. [25], randomly assigned patients with type I
diabetes into groups that maintained ‘‘normoglycemia’’
(HbA1c = 5.6) or hyperglycemia (HbA1c = 8.8) for 6 years.
After their intervention, which included no exercise training,
peak workload, VO2max were reduced in the hyperglycemic
but not in the normoglycemic group. In this context, our ﬁnd-
ings and those of Niranjen et al. [25] conﬁrm a relationship be-
tween aerobic ﬁtness and glycemic control and suggest that
careful glycemic control improves aerobic capacity in trained
and untrained subjects. In contrast, it is unclear whether aero-
bic training improves glycemic control.
The mechanism through which poor glycemic control inﬂu-
enced cardiac and pulmonary responses to maximal exercise is
an interesting area for further study. Autonomic dysfunction
may have inﬂuenced the hemodynamic exercise response in
the high-HbA1c group. Neurological impairment in subjects
with diabetes is strongly linked with glycemic control [26].
Pulmonary function is similarly affected by hyperglycemia.
Approximately 75% of young, nonsmoking individuals with
type I diabetes exhibit abnormal lung function [27]. Thesediabetes-speciﬁc limitations are most likely associated with
decreased pulmonary elasticity and loss of alveolar
microvascular volume caused by protein glycosylation in the
lung parenchyma and vascular endothelium [28,29]. These
physical restrictions manifest as decreased FVC, FEV1, and
FEF50, which mimic our ﬁndings in the high-HbA1c group
during peak exercise. Our ﬁnding that cardiac and pulmonary
capacities were impaired in the high-versus the low-HbA1c
group, combined with the previous ﬁnding that 6 year of nor-
moglycemia improves aerobic capacity without any exercise
training [25]. highlights the potential importance of chronic
glycemic control for athletes with type I diabetes.
The low-HbA1c group had an average HbA1c of 6.5%,
which is widely considered ‘‘good’’ glycemic control in this
population [29]. Although better glycemic control may have
further improved the cardiopulmonary response to exercise
in the low-HbA1c group, potential gains should be balanced
by the increased risk of exercise hypoglycemia when blood
glucose levels are maintained too low.Conclusion
Our study concludes that diabetic subjects show a decrease in
PFT values and VO2 max compared to non-diabetic subjects.
Also, uncontrolled diabetics are more prone to respiratory dys-
function than controlled diabetics. Intensive glycemic manage-
ment may reduce the risk of death through improved
476 M.M. El-Habashy et al.ventilatory function independent of other beneﬁcial effects.
The patients with diabetes are suggested to undergo pulmon-
ary function testing along with other investigations.
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